乙烯基甲醚和马来酸酐共聚物(PVME/MA)系列产品

Search documents
新开源:2025年上半年净利润1.39亿元 同比下降34.74%
Sou Hu Cai Jing· 2025-08-26 12:45
| | 本报告期 | 上年同期 | | --- | --- | --- | | 营业收入(元) | 644, 014, 332. 79 | 734,804,462.96 | | 归属于上市公司股东的净利 | 138, 956, 706. 00 | 212, 929, 814. 26 | | 润(元) | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | 129, 317, 734. 25 | 218, 300, 190. 74 | | (元) | | | | 经营活动产生的现金流量净 | 74, 385, 132. 17 | 158, 165, 912. 48 | | 额(元) | | | | 基本每股收益(元/股) | 0. 29 | 0. 45 | | 稀释每股收益(元/股) | 0. 29 | 0. 44 | | 加权平均净资产收益率 | 3.75% | 5.91% | | | 本报告期末 | 上年度末 | | 总资产(元) | 4, 695, 242, 883. 74 | 4, 372, 054, 795. 55 | | 归属于上市公司股东的净资 | 3, 778, 561, 272. ...
新开源(松江)全球研发转化生产基地盛大开业,打造生物医药产业新高地
Zheng Quan Shi Bao Wang· 2025-06-19 09:33
Core Viewpoint - The opening of the new R&D transformation production base by Xin Kai Yuan in Songjiang marks a significant milestone for the company and contributes to the development of the biopharmaceutical industry in the region [2][3][4] Group 1: Company Overview - Xin Kai Yuan is the first domestic high-tech enterprise focused on the production, R&D, and sales of PVP series products and PVME/MA series products, with over 1,000 clients globally [2] - The company has been planning its medical business headquarters in Shanghai Songjiang since 2018, aiming to strengthen its existing precision medicine and women's health businesses [2] - Xin Kai Yuan collaborates deeply with its invested companies, Huada Bio and Yongtai Bio, to establish a fully autonomous CAR-T cell production base with complete intellectual property rights [2] Group 2: Industry Impact - The establishment of the "Yuan Yin Nuo Fang" biopharmaceutical incubator and the signing of a commercial production base agreement for CAR-T cell drugs with Huada Bio will enhance production efficiency and reduce costs [3] - The new base aligns with the strategic goals of the Songjiang District, which aims to create a world-class biopharmaceutical industry cluster, thereby boosting R&D capabilities in cutting-edge fields like cell therapy and gene technology [3] - The operation of the new base is expected to drive innovation and international development in precision medicine and high-end fine chemicals in China [3][4]
博爱新开源医疗科技集团股份有限公司2024年年度报告摘要
Shang Hai Zheng Quan Bao· 2025-04-18 22:20
Core Viewpoint - The company has reported its annual financial results, highlighting its main business areas in fine chemicals and precision medicine, along with a proposed cash dividend distribution to shareholders [1][25]. Company Overview - The company specializes in fine chemicals and precision medicine, being the first in China to focus on the production, research, and sales of PVP series products and PVME/MA series products [5][25]. - The main products include PVP, which is widely used in pharmaceuticals, food processing, cosmetics, new energy, environmental water treatment, and other industrial fields [6][20]. Financial Highlights - The company has proposed a cash dividend of 2.5 yuan per 10 shares (including tax) based on a total of 484,700,005 shares, with no stock bonus [4][31]. - The company has undergone a change in its auditing firm to Zhongqin Wanxin Certified Public Accountants [3]. Business Applications - PVP products are utilized in various sectors: - **Pharmaceuticals**: Used as binders, stabilizers, and release agents in drug formulations [6][7]. - **Food Processing**: Acts as a clarifying agent and stabilizer [8][9]. - **Cosmetics**: Functions as a thickening agent and moisture-retaining agent [10][11]. - **New Energy**: Serves as a dispersant in lithium batteries and enhances photovoltaic cell efficiency [12][13]. - **Environmental Treatment**: Used in membrane materials and as inhibitors in gas transportation [14][15]. - **Other Industries**: Improves the performance of coatings, inks, textiles, and paper [16][18][19]. Strategic Developments - The company has approved investments in two entities, increasing its stake in Huadao Biological and Zhongqi Huiyun Technology [29]. - The company is focusing on expanding its precision medicine services, leveraging its technology in equipment, reagents, and medical services [24].